Jump to: Authorized Access | Attribution | Authorized Requests

Study Description

Pancreatic cancer patients with pathogenic variants in DNA repair genes may benefit from PARP inhibitor therapy, but efficacy beyond germline BRCA1/2 mutations remains uncertain. This multicenter phase II trial (NCT03601923) enrolled 32 patients with advanced pancreatic cancer harboring germline or somatic pathogenic variants in BRCA1, BRCA2, PALB2, ATM, or CHEK2 who had not progressed on prior platinum-based chemotherapy. Patients received niraparib 200-300 mg daily. Here we deposit the whole exome samples of six patients from the study (N=13 total samples). Patients P02, P03, P06, and P21 have matched tumor-normal blood pairs; patient P22 has a single tumor sample; and patient P30 has four tumor samples collected at different timepoints for longitudinal analysis.

Authorized Access
Publicly Available Data
  Link to other NCBI resources related to this study
Study Inclusion/Exclusion Criteria

Inclusion Criteria:

  • Advanced pancreatic cancer
  • Documented germline or somatic pathogenic variant in at least one of the following genes: BRCA1, BRCA2, PALB2, ATM, or CHEK2
  • No prior disease progression on platinum-based chemotherapy


Exclusion Criteria:

  • Prior progression on platinum-based therapy


Note: Only patients who consented to data sharing are included in this dbGaP submission (n=3 of 4 patients with whole exome sequencing data).

Selected Publications
Diseases/Traits Related to Study (MeSH terms)
Links to Related Genes
Authorized Data Access Requests
Study Attribution
  • Principal Investigator
    • James M. Cleary. Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA.
  • Co-Investigators
    • Brandon M. Huffman. Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA.
    • Miklos Diossy. Computational Health Informatics Program, Boston Children's Hospital, Boston, Massachusetts, USA; Danish Cancer Institute, Copenhagen, Denmark.
    • Matthew B. Yurgelun. Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA.
    • Nora Horick. Massachusetts General Hospital, Boston, Massachusetts, USA.
    • Yvonne Y. Li. Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
    • Jett Crowdis. Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA.
    • Huy Nguyen. Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
    • Kalindi Parmar. Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
    • Bose S. Kochupurakkal. Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
    • Leonard Vonk. Dana-Farber Cancer Institute, Boston, Massachusetts, USA; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.
    • Helen Lam. Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
    • Kaitlyn Ramsey. Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
    • Elizabeth Andrews. Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
    • Sarah C. Loeb. Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
    • Leigh Culnane. Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
    • Leah H. Biller. Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA.
    • Andrea J. Bullock. Harvard Medical School, Boston, Massachusetts, USA; Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
    • Andrea Enzinger. Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA.
    • Marios Giannakis. Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA.
    • Nadine McCleary. Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA.
    • Kimmie Ng. Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA.
    • Jonathan A. Nowak. Harvard Medical School, Boston, Massachusetts, USA; Brigham and Women's Hospital, Boston, Massachusetts, USA.
    • Anuj K. Patel. Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA.
    • Kimberly J. Perez. Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA.
    • Ahmed Rattani. Harvard Medical School, Boston, Massachusetts, USA; Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
    • Douglas A. Rubinson. Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA.
    • Benjamin L. Schlechter. Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA.
    • Harshabad Singh. Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA.
    • Mingyang Cai. Guardant Health, Redwood City, California, USA.
    • Srivatsan Raghavan. Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.
    • Jeffrey W. Clark. Harvard Medical School, Boston, Massachusetts, USA; Massachusetts General Hospital, Boston, Massachusetts, USA.
    • Mary Linton Peters. Harvard Medical School, Boston, Massachusetts, USA; Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
    • Caroline M. Weipert. Guardant Health, Redwood City, California, USA.
    • Brian M. Wolpin. Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA.
    • Alan D. D'Andrea. Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA.
    • Geoffrey I. Shapiro. Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA.
    • Andrew J. Aguirre. Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.
    • Zoltan Szallasi. Computational Health Informatics Program, Boston Children's Hospital, Boston, Massachusetts, USA; Danish Cancer Institute, Copenhagen, Denmark; Department of Bioinformatics, Semmelweis University, Budapest, Hungary.